IOP

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Retrieved on: 
Mercredi, mai 8, 2024
Pain, CRSP, Patient, SHR, Cas9, Cell, CRISPR, ALAS1, LNP, AHP, Gene editing, Angiotensin, Paratriathlon, RNA, IOP, ALA, Disease, Porphobilinogen, Liver, CRISPR Therapeutics, Gene, Eye, Society, Trabecular meshwork, MYOC, RAAS, Cardiovascular disease, BP, AGT, Biomarker, PBG, Therapy, Glaucoma

In addition, CRISPR Therapeutics announced the expansion of its in vivo pipeline with two new programs.

Key Points: 
  • In addition, CRISPR Therapeutics announced the expansion of its in vivo pipeline with two new programs.
  • “The expansion of our in vivo pipeline speaks to the scalability of the platform and the exceptional translation capabilities of our team.
  • The addition of two more programs, CTX340 and CTX450, utilizing this LNP delivery technology demonstrates the modularity and scalability of the platform.
  • In today’s presentation, the Company presented data demonstrating efficient and specific delivery to TM cells in mouse, non-human primate, and ex vivo human eyes.

Newport Healthcare Announces Specialized Substance Use Disorder Treatment for Teens and Young Adults

Retrieved on: 
Mercredi, mai 8, 2024
Dialectical behavior therapy, Fentanyl, Drug, Drug overdose, Chronic pain, EMDR, Cognitive behavioral therapy, MAT, Adventure therapy, Health, PTSD, Region, Trauma, Family therapy, Cocaine, IOP, Depression, Yoga, DBT, Nonoshita, Intensive outpatient program, Methamphetamine, Betty Ford Center, Music, CBT, Prohibition, PHP, Anxiety, Nursing

To address this persistent crisis, Newport Healthcare has announced specialized substance use disorder treatment for teens and young adults ages 12-35.

Key Points: 
  • To address this persistent crisis, Newport Healthcare has announced specialized substance use disorder treatment for teens and young adults ages 12-35.
  • Currently recognized as the leading treatment provider for teens and young adults with primary mental health disorders, Newport has expanded its programming to meet the needs of clients and families struggling with addiction.
  • "Now, with our full continuum of SUD care, we can support teens and young adults throughout their recovery process as they create the foundation for a thriving, substance-free life."
  • Newport offers substance use disorder treatment (often referred to as "rehab") for teens and young adults via residential treatment, Partial Hospitalization Programs (PHP), Intensive Outpatient Programs (IOP), Medication-Assisted Treatment (MAT), and detoxification services (available in select areas).

Injectsense First-in-Human Glaucoma Device Study Approved by Ethics Committee at Centro de la Vision Clinic

Retrieved on: 
Lundi, mai 6, 2024
FDA, University, Ecosystem, Safety, NIH, IDE, IOP, Research, Pressure, Patient, Eye, Physician, Cataract, SBIR, Glaucoma, PMA, Pharmaceutical industry

IOP is a key physiological marker that helps determine glaucoma risk and chances for disease progression. Injectsense's iOP-Connect™ implantable sensor offers doctors the unprecedented ability to see a patient's continuous diurnal IOP activity over decades -- without patient intervention. The measurements enable physicians to determine whether there have been pressure excursions outside of the patient's normal baseline and whether the patients are in an unstable or progressing state of glaucoma. These insights will make it possible to manage therapy effectiveness. 

Key Points: 
  • EMERYVILLE, Calif., May 6, 2024 /PRNewswire/ -- Injectsense Inc ., a sensor-enabled digital health company, announced that the ethics committee at the Centro de la Vision Clinic in Santiago, Chile, has approved a 20-patient study that will confirm safety and effectiveness of the company's ultra-miniature wireless pressure sensor, designed to continuously measure intra-ocular pressure (IOP) for glaucoma.
  • The study will be led by Dr. Juan Jose Mura , a glaucoma specialist at the clinic and an ophthalmologist at the University of Chile.
  • His research interests include surgical reconstruction of the anterior segment of the eye as well as cataract and glaucoma procedures.
  • Following the human study, Injectsense will continue its cooperation with key medical institutions and medical advisors to prepare post-IDE data development plans with a view towards patient enrollment.

A Decade of Dedication: Celebrating Innerspace Counseling's Milestone Anniversary

Retrieved on: 
Lundi, mai 6, 2024
Education, OLD, LPC, Prenatal development, Innerspace, Hope, NCC, Hospital, School, Heart, Partial hospitalization, Partnership, IOP, Life, Female, ACS, Mental health, Trust, Mother, Community, PHP, Walking, Growth, Nursing

This month, Innerspace Counseling celebrates an incredible ten years of providing such a sanctuary, dedicated to nurturing mental health and fostering community well-being.

Key Points: 
  • This month, Innerspace Counseling celebrates an incredible ten years of providing such a sanctuary, dedicated to nurturing mental health and fostering community well-being.
  • Over the past decade, Innerspace Counseling has distinguished itself as the only female owned and led Intensive Outpatient (IOP) and Partial Hospitalization (PHP) programs in New Jersey.
  • Innerspace also provides one of the few IOP and PHP programs specializing in primary mental health issues exclusively.
  • As we celebrate this milestone anniversary, we extend our deepest gratitude to everyone who has been part of our journey.

MYRA VISION'S CALIBREYE™ TITRATABLE GLAUCOMA THERAPY™ SURGICAL SYSTEM SHOWCASED AT OPHTHALMOLOGY CONFERENCES, RECEIVING BEST PAPER AWARD AND RECOGNITION OF FUTURE PROMISE IN GLAUCOMA CARE

Retrieved on: 
Mercredi, mai 1, 2024
Glaucoma surgery, Sale, University, Moran Eye Center, Lecture, TGT, Refractive surgery, Hospital, Safety, Research, Cataract, Paratriathlon, IOP, Manchester Royal Eye Hospital, NCT, Biomaterial, ASCRS, Intraocular pressure, Patient, Society, Physician, ICGS, EGS, Glaucoma, Trabeculectomy, Moorfields Eye Hospital, ARVO, Medical device

Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.

Key Points: 
  • Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.
  • The Calibreye shunt is designed to deliver an adjustable solution to control IOP in patients requiring low IOP.
  • While these devices have demonstrated an improvement in complication rates, achieving the IOP reductions necessary for these glaucoma patients remains challenging.
  • The Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System is for investigational use only and is not for sale in the U.S. or outside the U.S.

EDCare Brings Virtual Eating Disorder Treatment Services to Colorado, Kansas, and Nebraska

Retrieved on: 
Mardi, avril 30, 2024
Argyreia nervosa, LPC, Congressional Research Service, Telehealth, Housing, Insurance, IOP, Eating disorder, Intensive outpatient program, Mental health, Eating, Food, Helsinki University Central Hospital, PHP, COVID-19, Binge eating disorder, Nursing

DENVER, April 30, 2024 /PRNewswire/ -- EDCare, a leading provider of eating disorder treatment services, announced the expansion of its treatment options in Colorado, Kansas, and Nebraska to include a Virtual Intensive Outpatient Program (IOP).

Key Points: 
  • DENVER, April 30, 2024 /PRNewswire/ -- EDCare, a leading provider of eating disorder treatment services, announced the expansion of its treatment options in Colorado, Kansas, and Nebraska to include a Virtual Intensive Outpatient Program (IOP).
  • The virtual program offers flexible support that seamlessly integrates into individuals' busy schedules, providing evidence-based eating disorder treatment from the comfort of one's own homes.
  • Only about 20 percent of individuals with eating disorders are able to access treatment (Hart et al., 2011).
  • EDCare is in-network with most major insurance companies, including Colorado Medicaid and TRICARE®, and offers affordable housing accommodations for those seeking in-person treatment.

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Retrieved on: 
Jeudi, mai 2, 2024
FDA, Hydrus, MIGS, Telecanthus, Nature, Refractive surgery, News, Research, Depreciation, Cataract, Security (finance), IOP, DED, Webcast, Growth, Environment, District court, Patent, Intraocular pressure, Patient, Court, Society, Judgement, Glaucoma, Alcon, Ciclosporin, Standard of care, GAAP, Pharmaceutical industry

Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.

Key Points: 
  • Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.
  • The jury found that Sight Sciences’ asserted patents were willfully infringed, and awarded monetary damages for past infringement.
  • Sight Sciences reaffirms revenue guidance expectations for full year 2024 of approximately $81.0 million to $85.0 million, representing growth of approximately 0% to 5% growth compared to 2023.
  • Sight Sciences' management team will host a conference call today, May 2, 2024, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results

Retrieved on: 
Lundi, avril 22, 2024
Poster, Marshal of France, International, Drug, Bausch & Lomb, Research, Depreciation, Mass meeting, Sale, NCX, IOP, Kowa, ARVO, Patent, Patient, COVID-19, Nitric oxide, Ocular hypertension, Glaucoma, BlackRock, Pharmaceutical industry

“Nicox made good progress in 2023 as we move towards topline results of the Denali Phase 3 trial which we expect in H2 2025.

Key Points: 
  • “Nicox made good progress in 2023 as we move towards topline results of the Denali Phase 3 trial which we expect in H2 2025.
  • The Nicox Board of Directors has co-opted Dr Gavin Spencer, CEO of Nicox, as a Board member with effect from April 8, 2024.
  • The debt restructuring amendment which was agreed in principle between Nicox and BlackRock and announced on February 28, 2024 was signed.
  • The audit procedures on the 2023 statutory financial statements of Nicox SA have been completed and the certification report is in the process of being issued.

Acadia Healthcare Reports First Quarter 2024 Results, Affirms Full Year 2024 Guidance

Retrieved on: 
Mercredi, mai 1, 2024
Hospitals, General Health, Health, Mental Health, Joint Ventures, Hospital, CTC, Bed, Partnership, IOP, Orlando Health, Intensive outpatient program, Mental health, Patient, Acquisition, Adjustment, PHP, Growth

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2024.
  • Chris Hunter, Chief Executive Officer of Acadia Healthcare Company, remarked, “We are pleased with our solid financial and operating performance for the first quarter of 2024, with year-over-year top line growth of 9.1%.
  • Following the end of the quarter, Acadia opened a new 100-bed acute care hospital, Agave Ridge Behavioral Hospital, in Mesa, Arizona.
  • Acadia today affirmed its previously announced financial guidance for 2024, as follows:

Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class Iop-lowering Drug Candidate for Glaucoma

Retrieved on: 
Mardi, avril 30, 2024
Biotechnology, General Health, Health, Clinical Trials, Mayo Clinic, Osprey, Safety, EVP, Biochemistry, IOP, OHT, Hyperaemia, Therapy, Intraocular pressure, Patient, Trabecular meshwork, Ocular hypertension, General partnership, NTG, MBA, OAG, Molecular biology, Glaucoma, Ophthalmology, Overalls, Pharmaceutical industry

Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round.

Key Points: 
  • Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round.
  • Proceeds from the financing will support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower intraocular pressure (IOP) by targeting episcleral venous pressure (EVP).
  • “Qlaris is dedicated to developing new mechanisms of action that target unaddressed parameters within IOP regulation, an area of critical need.
  • Qlaris has the potential to demonstrate the importance of targeting EVP in the ongoing QLS‑111 Phase II trials and we look forward to the data from this innovative drug candidate.”